PHA3801 Lecture Notes - Lecture 12: Adme, Quinolone, Maltose
24 Jul 2018
School
Department
Course
Professor
Document Summary
Polypharmacy: concurrent use of multiple medications, inc w age of pt. Also common in pts w long- term chronic illnesses (e. g. aids). Should always be considered when unexpected drug effects seen in clinic. Ddi risk inc exponentially w # drugs received. Ddi"s most important for drugs w low ti, dose alteration or new drug may be necessary, not all ddi"s are bad. Minimise risk by id at-risk pt, knowing what drug types are culprits, understanding mechanistic basis. At-risk pt classes: elderly (polypharmacy, impaired homeostatic mechanisms clearance/metabolism), very young infants (immature drug clearance capacity), very ill (polypharmacy, impaired homeostasis, Drug classes commonly involved: typically, drugs involved in clinically-significant ddi"s have narrow ti. Inc the potential for interactions e. g. antiarrhythmics, anticoagulants, antipsychotics, immunosuppressants, hypoglycaemic agents, theophylline, anticonvulsants, antidepressants, digoxin, lithium nsaids. Mechanistic basis for ddis: understanding mechanism helps avoid ddis. Pharmacokinetic: when drug alters delivery of another drug to its site of action.
